Prostate cancer is one of the most common malignancies in males wherein 1 in 8 men are
diagnosed with this disease in their lifetime. The urgency to find novel therapeutic …

Abstract α 1-Adrenoceptor antagonists, have been documented to induce apoptosis and
reduce prostate tumor vascularity in benign and malignant prostate cells. The quinazoline …

Purpose: To verify if exposure to antihypertensive drugs was associated to prostate cancer
(PC) risk. Methods: We conducted a matched case-control study using record linkage …

Recent evidence suggests that the quinazoline-based α1-adrenoceptor antagonists,
doxazosin and terazosin, exhibit a potent apoptotic effect against prostate tumor epithelial …

Previous studies documented the ability of quinazoline-based α1-adrenoceptor antagonists
to induce apoptosis in prostate cancer cells via an α1-adrenoceptor-independent …

In this study, an effective, biocompatible and biodegradable co-polymer comprising of
chitosan (CS) and polyvinyl alcohol (PVA) hydrogels, chemically crosslinked and …

This review evaluates the role of α-adrenoceptor antagonists as a potential treatment of
prostate cancer (PCa). Cochrane, Google Scholar and Pubmed were accessed to retrieve …

Certain α1-adrenoreceptor antagonists induce significant apoptosis and impair tumor
vascularity without affecting cellular proliferation, effects specific to the quinazoline structure …

The quinazoline‐derived α1‐adrenoceptor antagonists, doxazosin and terazosin have been
recently shown to induce an anoikis effect in human prostate cancer cells and to suppress …

Purpose Cyclooxygenase-2 (COX-2) is a potential pharmacologic target for the prevention of
various malignancies, including prostate cancer. We conducted a randomized, double-blind …